Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics

Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q3 2026

Management view

• “Vertex achieved another quarter of excellent commercial results and pipeline advancement.” (CEO, President & Director Reshma Kewalramani) She highlighted that “Third quarter total revenue grew 12% year-on-year,” with growth “balanced coming from both the U.S. and international from CF and

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Source: seekingalpha.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.